231 related articles for article (PubMed ID: 33883258)
1. Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
Dubois SP; Miljkovic MD; Fleisher TA; Pittaluga S; Hsu-Albert J; Bryant BR; Petrus MN; Perera LP; Müller JR; Shih JH; Waldmann TA; Conlon KC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883258
[TBL] [Abstract][Full Text] [Related]
2. IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion.
Conlon KC; Potter EL; Pittaluga S; Lee CR; Miljkovic MD; Fleisher TA; Dubois S; Bryant BR; Petrus M; Perera LP; Hsu J; Figg WD; Peer CJ; Shih JH; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
Clin Cancer Res; 2019 Aug; 25(16):4945-4954. PubMed ID: 31142503
[TBL] [Abstract][Full Text] [Related]
3. IL-15 in the Combination Immunotherapy of Cancer.
Waldmann TA; Dubois S; Miljkovic MD; Conlon KC
Front Immunol; 2020; 11():868. PubMed ID: 32508818
[TBL] [Abstract][Full Text] [Related]
4. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
Conlon KC; Lugli E; Welles HC; Rosenberg SA; Fojo AT; Morris JC; Fleisher TA; Dubois SP; Perera LP; Stewart DM; Goldman CK; Bryant BR; Decker JM; Chen J; Worthy TA; Figg WD; Peer CJ; Sneller MC; Lane HC; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
J Clin Oncol; 2015 Jan; 33(1):74-82. PubMed ID: 25403209
[TBL] [Abstract][Full Text] [Related]
5. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J
Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197
[TBL] [Abstract][Full Text] [Related]
6. IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56
Dubois S; Conlon KC; Müller JR; Hsu-Albert J; Beltran N; Bryant BR; Waldmann TA
Cancer Immunol Res; 2017 Oct; 5(10):929-938. PubMed ID: 28842470
[TBL] [Abstract][Full Text] [Related]
7. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy.
Laprevotte E; Voisin G; Ysebaert L; Klein C; Daugrois C; Laurent G; Fournie JJ; Quillet-Mary A
J Immunol; 2013 Oct; 191(7):3634-40. PubMed ID: 23997218
[TBL] [Abstract][Full Text] [Related]
9. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human prolactin improves antitumor effects of murine natural killer cells in vitro and in vivo.
Sun R; Wei H; Zhang J; Li A; Zhang W; Tian Z
Neuroimmunomodulation; 2002-2003; 10(3):169-76. PubMed ID: 12481157
[TBL] [Abstract][Full Text] [Related]
11. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
12. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages.
Zhang M; Wen B; Anton OM; Yao Z; Dubois S; Ju W; Sato N; DiLillo DJ; Bamford RN; Ravetch JV; Waldmann TA
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10915-E10924. PubMed ID: 30373815
[TBL] [Abstract][Full Text] [Related]
13. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.
Cooley S; He F; Bachanova V; Vercellotti GM; DeFor TE; Curtsinger JM; Robertson P; Grzywacz B; Conlon KC; Waldmann TA; McKenna DH; Blazar BR; Weisdorf DJ; Miller JS
Blood Adv; 2019 Jul; 3(13):1970-1980. PubMed ID: 31266741
[TBL] [Abstract][Full Text] [Related]
14. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).
Pachynski RK; Morishima C; Szmulewitz R; Harshman L; Appleman L; Monk P; Bitting RL; Kucuk O; Millard F; Seigne JD; Fling SP; Maecker HT; Duault C; Ramchurren N; Hess B; D'Amico L; Lacroix A; Kaiser JC; Morre M; Grégoire A; Cheever M; Yu EY; Fong L
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452927
[TBL] [Abstract][Full Text] [Related]
15. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies.
Miljkovic MD; Dubois SP; Müller JR; Bryant B; Ma E; Conlon KC; Waldmann TA
Blood Adv; 2023 Feb; 7(3):384-394. PubMed ID: 35475910
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.
Meropol NJ; Barresi GM; Fehniger TA; Hitt J; Franklin M; Caligiuri MA
Cancer Immunol Immunother; 1998 Aug; 46(6):318-26. PubMed ID: 9756416
[TBL] [Abstract][Full Text] [Related]
19. IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood.
Sneller MC; Kopp WC; Engelke KJ; Yovandich JL; Creekmore SP; Waldmann TA; Lane HC
Blood; 2011 Dec; 118(26):6845-8. PubMed ID: 22067383
[TBL] [Abstract][Full Text] [Related]
20. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15.
Dunne J; Lynch S; O'Farrelly C; Todryk S; Hegarty JE; Feighery C; Doherty DG
J Immunol; 2001 Sep; 167(6):3129-38. PubMed ID: 11544298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
